Drug Profile
Ropocamptide - ProMore Pharma
Alternative Names: LL-37Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Karolinska Institute
- Developer ProMore Pharma
- Class Anti-infectives; Antiulcers; Peptides
- Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Inflammation mediator modulators; Keratinocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Leg ulcer